Stadler WM - Search Results

1

Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.

Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Szmulewitz RZ, et al. Among authors: stadler wm. Prostate. 2012 Feb 1;72(2):157-64. doi: 10.1002/pros.21416. Epub 2011 May 11. Prostate. 2012. PMID: 21563193 Free PMC article.

2

Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.

Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CW. Kim HL, et al. Among authors: stadler wm. Cancer Res. 2001 Apr 1;61(7):2833-7. Cancer Res. 2001. PMID: 11306453

3

Gene expression profiling of renal medullary carcinoma: potential clinical relevance.

Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, Vogelzang NJ, Teh BT. Yang XJ, et al. Among authors: stadler wm. Cancer. 2004 Mar 1;100(5):976-85. doi: 10.1002/cncr.20049. Cancer. 2004. PMID: 14983493 Free article.

4

Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.

Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW. Vander Griend DJ, et al. Among authors: stadler wm. Cancer Res. 2005 Dec 1;65(23):10984-91. doi: 10.1158/0008-5472.CAN-05-2382. Cancer Res. 2005. PMID: 16322247

5

Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.

Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W, Rinker-Schaeffer CW. Lotan TL, et al. J Pathol. 2007 Aug;212(4):386-94. doi: 10.1002/path.2194. J Pathol. 2007. PMID: 17577251

6

Sunitinib--a new standard of care for metastatic renal cell carcinoma.

Stadler WM, Szmulewitz RZ. Stadler WM, et al. Nat Clin Pract Oncol. 2007 Aug;4(8):458-9. doi: 10.1038/ncponc0882. Epub 2007 Jun 26. Nat Clin Pract Oncol. 2007. PMID: 17593923 No abstract available.

7

Adjuvant chemotherapy in lymph node positive bladder cancer.

Gofrit ON, Stadler WM, Zorn KC, Lin S, Silvestre J, Shalhav AL, Zagaja GP, Steinberg GD. Gofrit ON, et al. Among authors: stadler wm. Urol Oncol. 2009 Mar-Apr;27(2):160-4. doi: 10.1016/j.urolonc.2007.12.013. Epub 2008 Apr 28. Urol Oncol. 2009. PMID: 18440835 Clinical Trial.

8

The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.

Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM. Knight D, et al. Among authors: stadler wm. Prostate. 2009 Feb 1;69(2):142-8. doi: 10.1002/pros.20864. Prostate. 2009. PMID: 18942640

9

FYN is overexpressed in human prostate cancer.

Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. Posadas EM, et al. Among authors: stadler wm. BJU Int. 2009 Jan;103(2):171-7. doi: 10.1111/j.1464-410X.2008.08009.x. Epub 2008 Oct 16. BJU Int. 2009. PMID: 18990162 Free PMC article.

10

A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.

Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. Szmulewitz R, et al. Among authors: stadler wm. Eur Urol. 2009 Jul;56(1):97-103. doi: 10.1016/j.eururo.2009.02.022. Epub 2009 Feb 27. Eur Urol. 2009. PMID: 19282098 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page